Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Outlook Therapeutics (OTLK) Other Working Capital Changes (2016 - 2025)

Outlook Therapeutics has reported Other Working Capital Changes over the past 7 years, most recently at -$13499.0 for Q4 2025.

Quarterly Other Working Capital Changes fell 404.37% to -$13499.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.2 million through Dec 2025, down 49423.52% year-over-year, with the annual reading at $25716.0 for FY2025, 166.63% up from the prior year.
Other Working Capital Changes was -$13499.0 for Q4 2025 at Outlook Therapeutics, down from $6.1 million in the prior quarter.
Over five years, Other Working Capital Changes peaked at $6.1 million in Q3 2025 and troughed at -$13499.0 in Q4 2025.